1 528 122 ASTHMA EPIGENETICS. ASTHMA IS THE MOST COMMON CHRONIC DISEASE OF CHILDHOOD, AND A GROWING BODY OF EVIDENCE INDICATES THAT EPIGENETIC VARIATIONS MAY MEDIATE THE EFFECTS OF ENVIRONMENTAL EXPOSURES ON THE DEVELOPMENT AND NATURAL HISTORY OF ASTHMA. EPIGENETICS IS THE STUDY OF MITOTICALLY OR MEIOTICALLY HERITABLE CHANGES IN GENE EXPRESSION THAT OCCUR WITHOUT DIRECTLY ALTERING THE DNA SEQUENCE. DNA METHYLATION, HISTONE MODIFICATIONS AND MICRORNAS ARE MAJOR EPIGENETIC VARIATIONS IN HUMANS THAT ARE CURRENTLY BEING INVESTIGATED FOR ASTHMA ETIOLOGY AND NATURAL HISTORY. DNA METHYLATION RESULTS FROM ADDITION OF A METHYL GROUP TO THE 5 POSITION OF A CYTOSINE RING AND OCCURS ALMOST EXCLUSIVELY ON A CYTOSINE IN A CPG DINUCLEOTIDE. HISTONE MODIFICATIONS INVOLVE POSTTRANSLATIONAL MODIFICATIONS SUCH AS ACETYLATION, METHYLATION, PHOSPHORYLATION AND UBIQUITINATION ON THE TAILS OF CORE HISTONES. MICRORNAS ARE SHORT ~22 NUCLEOTIDE LONG, NON-CODING, SINGLE-STRANDED RNAS THAT BINDS TO COMPLEMENTARY SEQUENCES IN THE TARGET MRNAS, USUALLY RESULTING IN GENE SILENCING. WHILE MANY STUDIES HAVE DOCUMENTED RELATIONSHIPS OF ENVIRONMENTAL EXPOSURES THAT HAVE BEEN IMPLICATED IN ASTHMA ETIOLOGY WITH EPIGENETIC ALTERATIONS, TO DATE, FEW STUDIES HAVE DIRECTLY LINKED EPIGENETIC VARIATIONS WITH ASTHMA DEVELOPMENT. THERE ARE SEVERAL METHODOLOGICAL CHALLENGES IN STUDYING THE EPIGENETICS OF ASTHMA. IN THIS CHAPTER, THE INFLUENCE OF EPIGENETIC VARIATIONS ON ASTHMA PATHOPHYSIOLOGY, METHODOLOGICAL CONCERNS IN CONDUCTING EPIGENETIC RESEARCH AND FUTURE DIRECTION OF ASTHMA EPIGENETICS RESEARCH ARE DISCUSSED. 2014 2 2618 29 EPIGENOME-MODIFYING TOOLS IN ASTHMA. ASTHMA IS A CHRONIC DISEASE WHICH CAUSES RECURRENT BREATHLESSNESS AFFECTING 300 MILLION PEOPLE WORLDWIDE OF WHOM 250,000 DIE ANNUALLY. THE EPIGENOME IS A SET OF HERITABLE MODIFICATIONS AND TAGS THAT AFFECT THE GENOME WITHOUT CHANGING THE INTRINSIC DNA SEQUENCE. THESE MARKS INCLUDE DNA METHYLATION, MODIFICATIONS TO HISTONE PROTEINS AROUND WHICH DNA IS WRAPPED AND EXPRESSION OF NONCODING RNA. ALTERATIONS IN ALL OF THESE PROCESSES HAVE BEEN REPORTED IN PATIENTS WITH ASTHMA. IN SOME CASES THESE DIFFERENCES ARE LINKED TO DISEASE SEVERITY AND SUSCEPTIBILITY AND MAY ACCOUNT FOR THE LIMITED VALUE OF GENETIC STUDIES IN ASTHMA. ANIMAL MODELS OF ASTHMA SUGGEST THAT EPIGENETIC MODIFICATIONS AND PROCESSES ARE LINKED TO ASTHMA AND MAY BE TRACTABLE TARGETS FOR THERAPEUTIC INTERVENTION. 2015 3 2527 26 EPIGENETICS APPROACHES TOWARD PRECISION MEDICINE FOR IDIOPATHIC PULMONARY FIBROSIS: FOCUS ON DNA METHYLATION. GENETIC INFORMATION IS NOT TRANSMITTED SOLELY BY DNA BUT BY THE EPIGENETICS PROCESS. EPIGENETICS DESCRIBES MOLECULAR MISSING LINK PATHWAYS THAT COULD BRIDGE THE GAP BETWEEN THE GENETIC BACKGROUND AND ENVIRONMENTAL RISK FACTORS THAT CONTRIBUTE TO THE PATHOGENESIS OF PULMONARY FIBROSIS. SPECIFIC EPIGENETIC PATTERNS, ESPECIALLY DNA METHYLATION, HISTONE MODIFICATIONS, LONG NON-CODING, AND MICRORNA (MIRNAS), AFFECT THE ENDOPHENOTYPES UNDERLYING THE DEVELOPMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF). AMONG ALL THE EPIGENETIC MARKS, DNA METHYLATION MODIFICATIONS HAVE BEEN THE MOST WIDELY STUDIED IN IPF. THIS REVIEW SUMMARIZES THE CURRENT KNOWLEDGE CONCERNING DNA METHYLATION CHANGES IN PULMONARY FIBROSIS AND DEMONSTRATES A PROMISING NOVEL EPIGENETICS-BASED PRECISION MEDICINE. 2023 4 2560 40 EPIGENETICS IN THE DEVELOPMENT, MODIFICATION, AND PREVENTION OF CARDIOVASCULAR DISEASE. EPIGENETICS HAS MAJOR RELEVANCE TO ALL DISEASE PROCESSES; CARDIOVASCULAR (CV) DISEASE AND ITS RELATED CONDITIONS ARE NO EXCEPTION. EPIGENETICS IS DEFINED AS THE STUDY OF HERITABLE ALTERATIONS IN GENE EXPRESSION, OR CELLULAR PHENOTYPE, AND GOES FAR BEYOND A PURE GENETIC APPROACH. A MORE PRECISE DEFINITION IS THAT EPIGENETICS REPRESENTS ALL THE MEIOTICALLY AND MITOTICALLY INHERITED CHANGES IN GENE EXPRESSION THAT ARE NOT ENCODED ON THE DEOXYRIBONUCLEIC ACID (DNA) SEQUENCE ITSELF. MAJOR EPIGENETIC MECHANISMS ARE MODIFICATIONS OF HISTONE PROTEINS IN CHROMATIN AND DNA METHYLATION (WHICH DOES NOT ALTER THE DNA SEQUENCE). THERE IS INCREASING EVIDENCE FOR THE INVOLVEMENT OF EPIGENETICS IN HUMAN DISEASE SUCH AS CANCER, INFLAMMATORY DISEASE AND CV DISEASE. OTHER CHRONIC DISEASES ARE ALSO SUSCEPTIBLE TO EPIGENETIC MODIFICATION SUCH AS METABOLIC DISEASES INCLUDING OBESITY, METABOLIC SYNDROME, AND DIABETES MELLITUS. THERE IS MUCH EVIDENCE FOR THE MODIFICATION OF EPIGENETICS BY NUTRITION AND EXERCISE. THROUGH THESE MODIFICATIONS, THERE IS INFINITE POTENTIAL FOR BENEFIT FOR THE FETUS, THE NEWBORN, AND THE INDIVIDUAL AS WELL AS POPULATION EFFECTS. ASSOCIATION WITH CV DISEASE, INCLUDING CORONARY HEART DISEASE AND PERIPHERAL VASCULAR DISEASE, IS EVIDENT THROUGH EPIGENETIC RELATIONSHIPS AND MODIFICATION BY MAJOR CV RISK FACTORS SUCH AS TOBACCO ABUSE. AGING ITSELF MAY BE ALTERED BY EPIGENETIC MODIFICATION. KNOWLEDGE OF EPIGENETICS AND ITS RELEVANCE TO THE DEVELOPMENT, MODIFICATION, AND PREVENTION OF CV DISEASE IS IN A VERY PRELIMINARY STAGE BUT HAS AN INFINITE FUTURE. 2015 5 4781 25 NUTRIEPIGENOMICS AND MALNUTRITION. EPIGENETICS IS DEFINED AS THE MODULATION OF GENE EXPRESSION WITHOUT CHANGES TO THE UNDERLYING DNA SEQUENCE. EPIGENETIC ALTERATIONS, AS A CONSEQUENCE OF IN UTERO MALNUTRITION, MAY PLAY A ROLE IN SUSCEPTIBILITY TO DEVELOP ADULTHOOD DISEASES AND INHERITANCE. HOWEVER, THE MECHANISTIC LINK BETWEEN EPIGENETIC MODIFICATIONS AND ABNORMALITIES IN NUTRITION REMAINS ELUSIVE. THIS REVIEW PROVIDES AN UPDATE ON THE ASSOCIATION OF SUBOPTIMAL NUTRITIONAL ENVIRONMENT AND THE HIGH PROPENSITY TO PRODUCE ADULT-ONSET CHRONIC ILLNESSES WITH A PARTICULAR FOCUS ON MODIFICATIONS IN GENOME FUNCTIONS THAT OCCUR WITHOUT ALTERATIONS TO THE DNA SEQUENCE. WE WILL MENTION THE DRIVERS OF THE PHENOTYPE AND PATTERN OF EPIGENETIC MARKERS SET DOWN DURING THE REPROGRAMMING ALONG WITH NOVEL PREVENTATIVE AND THERAPEUTIC STRATEGIES. NEW KNOWLEDGE OF EPIGENETIC ALTERATIONS IS OPENING A GATE TOWARD PERSONALIZED MEDICINE. 2017 6 1873 28 EMERGING ROLE OF MICRORNAS AND LONG NON-CODING RNAS IN SJOGREN'S SYNDROME. SJOGREN'S SYNDROME (SS) IS A CHRONIC AUTOIMMUNE INFLAMMATORY DISEASE. IT IS CONSIDERED A MULTIFACTORIAL PATHOLOGY, IN WHICH UNDERLYING GENETIC PREDISPOSITION, EPIGENETIC MECHANISMS AND ENVIRONMENTAL FACTORS CONTRIBUTE TO DEVELOPMENT. THE EPIGENETIC REGULATIONS REPRESENT A LINK BETWEEN GENETIC PREDISPOSITION AND ENVIRONMENTAL FACTORS. RECENT STUDIES SUGGESTED A REGULATORY ROLE FOR NON-CODING RNAS IN CRITICAL BIOLOGICAL AND DISEASE PROCESSES. AMONG NON-CODING RNAS, MICRORNAS (MIRNAS) AND LONG NON-CODING RNAS (LNCRNAS) PLAY A CRITICAL ROLE IN THE POST-TRANSCRIPTIONAL MRNA EXPRESSION, FORMING A COMPLEX NETWORK OF GENE EXPRESSION REGULATION. THIS REVIEW AIMS TO GIVE AN OVERVIEW OF THE LATEST STUDIES THAT HAVE INVESTIGATED THE ROLE OF MIRNAS AND LNCRNAS IN THE SS. WE INCLUDED PAPERS THAT INVESTIGATED THE EXPRESSION OF NON-CODING RNAS ON DIFFERENT TISSUES, IN PARTICULAR ON PERIPHERAL BLOOD MONONUCLEAR CELLS AND SALIVARY GLANDS. HOWEVER, REGARDING THE INVOLVEMENT OF NON-CODING RNAS GENETIC VARIABILITY IN SS SUSCEPTIBILITY VERY FEW DATA ARE AVAILABLE. FURTHER RESEARCH COULD HELP TO ELUCIDATE UNDERLYING PATHOGENIC PROCESSES OF SS AND PROVIDE NEW OPPORTUNITIES FOR THE DEVELOPMENT OF TARGETED THERAPIES. 2021 7 6128 26 THE EPIGENETIC PARADIGM IN PERIODONTITIS PATHOGENESIS. EPIGENOME REFERS TO "EPI" MEANING OUTSIDE THE "GENOME." EPIGENETICS IS THE FIELD OF STUDY OF THE EPIGENOME. EPIGENETIC MODIFICATIONS INCLUDE CHANGES IN THE PROMOTER CPG ISLANDS, MODIFICATIONS OF HISTONE PROTEIN STRUCTURE, POSTTRANSLATIONAL REPRESSION BY MICRO-RNA WHICH CONTRIBUTES TO THE ALTERATION OF GENE EXPRESSION. EPIGENETICS PROVIDES AN UNDERSTANDING OF THE ROLE OF GENE-ENVIRONMENT INTERACTIONS ON DISEASE PHENOTYPE ESPECIALLY IN COMPLEX MULTIFACTORIAL DISEASES. PERIODONTITIS IS A CHRONIC INFLAMMATORY DISORDER THAT AFFECTS THE SUPPORTING STRUCTURES OF THE TOOTH. THE ROLE OF THE GENOME (IN TERMS OF GENETIC POLYMORPHISMS) IN PERIODONTITIS PATHOGENESIS HAS BEEN EXAMINED IN NUMEROUS STUDIES, AND CHRONIC PERIODONTITIS HAS BEEN ESTABLISHED AS A POLYGENIC DISORDER. THE POTENTIAL ROLE OF EPIGENETIC MODIFICATIONS IN THE VARIOUS FACETS OF PATHOGENESIS OF PERIODONTITIS IS DISCUSSED IN THIS PAPER BASED ON THE AVAILABLE LITERATURE. 2015 8 2542 32 EPIGENETICS IN KIDNEY DISEASES. EPIGENETICS EXAMINES HERITABLE CHANGES IN DNA AND ITS ASSOCIATED PROTEINS EXCEPT MUTATIONS IN GENE SEQUENCE. EPIGENETIC REGULATION PLAYS FUNDAMENTAL ROLES IN KIDNEY CELL BIOLOGY THROUGH THE ACTION OF DNA METHYLATION, CHROMATIN MODIFICATION VIA EPIGENETIC REGULATORS AND NON-CODING RNA SPECIES. KIDNEY DISEASES, INCLUDING ACUTE KIDNEY INJURY, CHRONIC KIDNEY DISEASE, DIABETIC KIDNEY DISEASE AND RENAL FIBROSIS ARE MULTISTEP PROCESSES ASSOCIATED WITH NUMEROUS MOLECULAR ALTERATIONS EVEN IN INDIVIDUAL KIDNEY CELLS. EPIGENETIC ALTERATIONS, INCLUDING ANOMALOUS DNA METHYLATION, ABERRANT HISTONE ALTERATIONS AND CHANGES OF MICRORNA EXPRESSION ALL CONTRIBUTE TO KIDNEY PATHOGENESIS. THESE CHANGES ALTER THE GENOME-WIDE EPIGENETIC SIGNATURES AND DISRUPT ESSENTIAL PATHWAYS THAT PROTECT RENAL CELLS FROM UNCONTROLLED GROWTH, APOPTOSIS AND DEVELOPMENT OF OTHER RENAL ASSOCIATED SYNDROMES. MOLECULAR CHANGES IMPACT CELLULAR FUNCTION WITHIN KIDNEY CELLS AND ITS MICROENVIRONMENT TO DRIVE AND MAINTAIN DISEASE PHENOTYPE. IN THIS CHAPTER, WE BRIEFLY SUMMARIZE EPIGENETIC MECHANISMS IN FOUR KIDNEY DISEASES INCLUDING ACUTE KIDNEY INJURY, CHRONIC KIDNEY DISEASE, DIABETIC KIDNEY DISEASE AND RENAL FIBROSIS. WE PRIMARILY FOCUS ON CURRENT KNOWLEDGE ABOUT THE GENOME-WIDE PROFILING OF DNA METHYLATION AND HISTONE MODIFICATION, AND EPIGENETIC REGULATION ON SPECIFIC GENE(S) IN THE PATHOPHYSIOLOGY OF THESE DISEASES AND THE TRANSLATIONAL POTENTIAL OF IDENTIFYING NEW BIOMARKERS AND TREATMENT FOR PREVENTION AND THERAPY. INCORPORATING EPIGENOMIC TESTING INTO CLINICAL RESEARCH IS ESSENTIAL TO ELUCIDATE NOVEL EPIGENETIC BIOMARKERS AND DEVELOP PRECISION MEDICINE USING EMERGING THERAPIES. 2021 9 2609 34 EPIGENETICS: A POTENTIAL KEY MECHANISM INVOLVED IN THE PATHOGENESIS OF CARDIORENAL SYNDROMES. EPIGENETICS IS DEFINED AS THE HERITABLE CHANGES IN GENE EXPRESSION PATTERNS WHICH ARE NOT DIRECTLY ENCODED BY MODIFICATIONS IN THE NUCLEOTIDE DNA SEQUENCE OF THE GENOME, INCLUDING HIGHER ORDER CHROMATIN ORGANIZATION, DNA METHYLATION, CYTOSINE MODIFICATIONS, COVALENT HISTONE TAIL MODIFICATIONS, AND SHORT NON-CODING RNA MOLECULES. RECENTLY, MUCH ATTENTION HAS BEEN PAID TO THE ROLE AND THE FUNCTION OF EPIGENETICS AND EPIMUTATIONS IN THE CELLULAR AND SUBCELLULAR PATHWAYS AND IN THE REGULATION OF GENES IN THE SETTING OF BOTH KIDNEY AND CARDIOVASCULAR DISEASE. INDEED, DEREGULATION OF HISTONE ALTERATIONS HAS BEEN HIGHLIGHTED IN A LARGE SPECTRUM OF RENAL AND CARDIAC DISEASE, INCLUDING CHRONIC AND ACUTE RENAL INJURY, RENAL AND CARDIAC FIBROSIS, CARDIAC HYPERTROPHY AND FAILURE, KIDNEY CONGENITAL ANOMALIES, RENAL HYPOXIA, AND DIABETIC RENAL COMPLICATIONS. NEVERTHELESS, THE ROLE OF EPIGENETICS IN THE PATHOGENESIS AND PATHOPHYSIOLOGY OF CARDIORENAL SYNDROMES IS CURRENTLY UNDEREXPLORED. GIVEN THE SIGNIFICANT CLINICAL RELEVANCE OF HEART-KIDNEY CROSSTALK, EFFORTS IN THE RESEARCH FOR NEW ACTION MECHANISMS CONCURRENTLY OPERATING IN BOTH PATHOLOGIES ARE THUS OF MAXIMUM INTEREST. THIS REVIEW FOCUSES ON EPIGENETIC MECHANISMS INVOLVED IN HEART AND KIDNEY DISEASE, AND THEIR POSSIBLE ROLE IN THE SETTING OF CARDIORENAL SYNDROMES. 2018 10 5325 31 PULMONARY PATHOGEN-INDUCED EPIGENETIC MODIFICATIONS. EPIGENETICS GENERALLY INVOLVES GENETIC CONTROL BY FACTORS OTHER THAN OUR OWN DNA SEQUENCE. RECENT RESEARCH HAS FOCUSED ON DELINEATING THE MECHANISMS OF TWO MAJOR EPIGENETIC PHENOMENA: DNA METHYLATION AND HISTONE MODIFICATION. AS EPIGENETICS INVOLVES MANY CELLULAR PROCESSES, IT IS NO SURPRISE THAT IT CAN ALSO INFLUENCE DISEASE-ASSOCIATED GENE EXPRESSION. A DIRECT LINK BETWEEN RESPIRATORY INFECTIONS, HOST CELL EPIGENETIC REGULATIONS, AND CHRONIC LUNG DISEASES IS STILL UNKNOWN. RECENT STUDIES HAVE REVEALED BACTERIUM- OR VIRUS-INDUCED EPIGENETIC CHANGES IN THE HOST CELLS. IN THIS REVIEW, WE FOCUSED ON RESPIRATORY PATHOGENS (VIRUSES, BACTERIA, AND FUNGI) INDUCED EPIGENETIC MODULATIONS (DNA METHYLATION AND HISTONE MODIFICATION) THAT MAY CONTRIBUTE TO LUNG DISEASE PATHOPHYSIOLOGY BY PROMOTING HOST DEFENSE OR ALLOWING PATHOGEN PERSISTENCE. 2023 11 607 33 BEYOND GENETICS: EPIGENETIC CODE IN CHRONIC KIDNEY DISEASE. EPIGENETICS REFERS TO A HERITABLE CHANGE IN THE PATTERN OF GENE EXPRESSION THAT IS MEDIATED BY A MECHANISM SPECIFICALLY NOT DUE TO ALTERATIONS IN THE PRIMARY NUCLEOTIDE SEQUENCE. WELL-KNOWN EPIGENETIC MECHANISMS ENCOMPASS DNA METHYLATION, CHROMATIN REMODELING (HISTONE MODIFICATIONS), AND RNA INTERFERENCE. FUNCTIONALLY, EPIGENETICS PROVIDES AN EXTRA LAYER OF TRANSCRIPTIONAL CONTROL AND PLAYS A CRUCIAL ROLE IN NORMAL PHYSIOLOGICAL DEVELOPMENT, AS WELL AS IN PATHOLOGICAL CONDITIONS. ABERRANT DNA METHYLATION IS IMPLICATED IN IMMUNE DYSFUNCTION, INFLAMMATION, AND INSULIN RESISTANCE. EPIGENETIC CHANGES MAY BE RESPONSIBLE FOR 'METABOLIC MEMORY' AND DEVELOPMENT OF MICRO- AND MACROVASCULAR COMPLICATIONS OF DIABETES. MICRORNAS ARE CRITICAL IN THE MAINTENANCE OF GLOMERULAR HOMEOSTASIS AND HENCE RNA INTERFERENCE MAY BE IMPORTANT IN THE PROGRESSION OF RENAL DISEASE. RECENT STUDIES HAVE SHOWN THAT EPIGENETIC MODIFICATIONS ORCHESTRATE THE EPITHELIAL-MESENCHYMAL TRANSITION AND EVENTUALLY FIBROSIS OF THE RENAL TISSUE. OXIDATIVE STRESS, INFLAMMATION, HYPERHOMOCYSTEINEMIA, AND UREMIC TOXINS COULD INDUCE EPIMUTATIONS IN CHRONIC KIDNEY DISEASE. EPIGENETIC ALTERATIONS ARE ASSOCIATED WITH INFLAMMATION AND CARDIOVASCULAR DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE. REVERSIBLE NATURE OF THE EPIGENETIC CHANGES GIVES A UNIQUE OPPORTUNITY TO HALT OR EVEN REVERSE THE DISEASE PROCESS THROUGH TARGETED THERAPEUTIC STRATEGIES. 2011 12 3706 31 INFLUENCE OF GENETICS ON DISEASE SUSCEPTIBILITY AND PROGRESSION. FOR MANY CHRONIC DISEASES, THE INFLUENCE OF GENETICS IS COMPLEX AND PHENOTYPES DO NOT CONFORM TO SIMPLE MENDELIAN PATTERNS OF INHERITANCE. DISCUSSED HERE ARE TWO TYPES OF GENETIC INFLUENCES ON HEALTHY AGING. THE FIRST INVOLVES VARIATION IN THE GENE SEQUENCE ITSELF AND HOW THIS MAY INFLUENCE DISEASE SUSCEPTIBILITY, PROGRESSION, AND SEVERITY, INTERACTING WITH OTHER RECOGNIZED RISK FACTORS. THE SECOND INVOLVES EPIGENETIC REGULATORY MECHANISMS THAT MAY POTENTIALLY PROVIDE INSIGHT INTO HOW ENVIRONMENTAL INFLUENCES AFFECT THE EXPRESSED GENOME, THUS IMPROVING OUR UNDERSTANDING OF THE GENETIC MECHANISMS UNDERLYING MULTIFACTORIAL DISEASES. THE INTERLEUKIN-1 FAMILY OF CYTOKINES CAN BE USED TO ILLUSTRATE HOW GENETIC SEQUENCE VARIATION MAY AFFECT SUCH DISEASES. THIS CYTOKINE FAMILY PLAYS A KEY ROLE IN MEDIATING INFLAMMATION, WHICH IS NOW UNDERSTOOD TO BE A CENTRAL COMPONENT OF A GROWING NUMBER OF CHRONIC DISEASES. RECENT WORK HAS REVEALED MANY SEQUENCE VARIATIONS IN THE REGULATORY DNA OF GENES ENCODING IMPORTANT MEMBERS OF THE INTERLEUKIN-1 FAMILY, AND THESE VARIATIONS ARE ASSOCIATED WITH DIFFERENTIAL EFFECTS ON THE INFLAMMATORY RESPONSE. THE INTERACTIONS OF ENVIRONMENTAL FACTORS WITH BOTH DNA SEQUENCE VARIATIONS AND EPIGENETIC MODIFICATIONS ARE LIKELY TO DETERMINE THE PHENOTYPES OF MULTIFACTORIAL DISEASES OF AGING AS WELL AS THE PHENOTYPE OF HEALTHY AGING. 2007 13 1396 46 DIET INDUCED EPIGENETIC CHANGES AND THEIR IMPLICATIONS FOR HEALTH. DIETARY EXPOSURES CAN HAVE CONSEQUENCES FOR HEALTH YEARS OR DECADES LATER AND THIS RAISES QUESTIONS ABOUT THE MECHANISMS THROUGH WHICH SUCH EXPOSURES ARE 'REMEMBERED' AND HOW THEY RESULT IN ALTERED DISEASE RISK. THERE IS GROWING EVIDENCE THAT EPIGENETIC MECHANISMS MAY MEDIATE THE EFFECTS OF NUTRITION AND MAY BE CAUSAL FOR THE DEVELOPMENT OF COMMON COMPLEX (OR CHRONIC) DISEASES. EPIGENETICS ENCOMPASSES CHANGES TO MARKS ON THE GENOME (AND ASSOCIATED CELLULAR MACHINERY) THAT ARE COPIED FROM ONE CELL GENERATION TO THE NEXT, WHICH MAY ALTER GENE EXPRESSION, BUT WHICH DO NOT INVOLVE CHANGES IN THE PRIMARY DNA SEQUENCE. THESE INCLUDE THREE DISTINCT, BUT CLOSELY INTER-ACTING, MECHANISMS INCLUDING DNA METHYLATION, HISTONE MODIFICATIONS AND NON-CODING MICRORNAS (MIRNA) WHICH, TOGETHER, ARE RESPONSIBLE FOR REGULATING GENE EXPRESSION NOT ONLY DURING CELLULAR DIFFERENTIATION IN EMBRYONIC AND FOETAL DEVELOPMENT BUT ALSO THROUGHOUT THE LIFE-COURSE. THIS REVIEW SUMMARIZES THE GROWING EVIDENCE THAT NUMEROUS DIETARY FACTORS, INCLUDING MICRONUTRIENTS AND NON-NUTRIENT DIETARY COMPONENTS SUCH AS GENISTEIN AND POLYPHENOLS, CAN MODIFY EPIGENETIC MARKS. IN SOME CASES, FOR EXAMPLE, EFFECTS OF ALTERED DIETARY SUPPLY OF METHYL DONORS ON DNA METHYLATION, THERE ARE PLAUSIBLE EXPLANATIONS FOR THE OBSERVED EPIGENETIC CHANGES, BUT TO A LARGE EXTENT, THE MECHANISMS RESPONSIBLE FOR DIET-EPIGENOME-HEALTH RELATIONSHIPS REMAIN TO BE DISCOVERED. IN ADDITION, RELATIVELY LITTLE IS KNOWN ABOUT WHICH EPIGENOMIC MARKS ARE MOST LABILE IN RESPONSE TO DIETARY EXPOSURES. GIVEN THE PLASTICITY OF EPIGENETIC MARKS AND THEIR RESPONSIVENESS TO DIETARY FACTORS, THERE IS POTENTIAL FOR THE DEVELOPMENT OF EPIGENETIC MARKS AS BIOMARKERS OF HEALTH FOR USE IN INTERVENTION STUDIES. 2011 14 2220 30 EPIGENETIC MODIFICATIONS IN NEUROPATHIC PAIN. NEUROPATHIC PAIN (NP) IS A COMMON SYMPTOM IN MANY DISEASES OF THE SOMATOSENSORY NERVOUS SYSTEM, WHICH SEVERELY AFFECTS THE PATIENT'S QUALITY OF LIFE. EPIGENETICS ARE HERITABLE ALTERATIONS IN GENE EXPRESSION THAT DO NOT CAUSE PERMANENT CHANGES IN THE DNA SEQUENCE. EPIGENETIC MODIFICATIONS CAN AFFECT GENE EXPRESSION AND FUNCTION AND CAN ALSO MEDIATE CROSSTALK BETWEEN GENES AND THE ENVIRONMENT. INCREASING EVIDENCE SHOWS THAT EPIGENETIC MODIFICATIONS, INCLUDING DNA METHYLATION, HISTONE MODIFICATION, NON-CODING RNA, AND RNA MODIFICATION, ARE INVOLVED IN THE DEVELOPMENT AND MAINTENANCE OF NP. IN THIS REVIEW, WE FOCUS ON THE CURRENT KNOWLEDGE OF EPIGENETIC MODIFICATIONS IN THE DEVELOPMENT AND MAINTENANCE OF NP. THEN, WE ILLUSTRATE DIFFERENT FACETS OF EPIGENETIC MODIFICATIONS THAT REGULATE GENE EXPRESSION AND THEIR CROSSTALK. FINALLY, WE DISCUSS THE BURGEONING EVIDENCE SUPPORTING THE POTENTIAL OF EMERGING EPIGENETIC THERAPIES, WHICH HAS BEEN VALUABLE IN UNDERSTANDING MECHANISMS AND OFFERS NOVEL AND POTENT TARGETS FOR NP THERAPY. 2021 15 2399 27 EPIGENETIC REPROGRAMMING OF HOST GENES IN VIRAL AND MICROBIAL PATHOGENESIS. ONE OF THE KEY QUESTIONS IN THE STUDY OF MAMMALIAN GENE REGULATION IS HOW EPIGENETIC METHYLATION PATTERNS ON HISTONES AND DNA ARE INITIATED AND ESTABLISHED. THESE STABLE, HERITABLE, COVALENT MODIFICATIONS ARE LARGELY ASSOCIATED WITH THE REPRESSION OR SILENCING OF GENE TRANSCRIPTION, AND WHEN DEREGULATED CAN BE INVOLVED IN THE DEVELOPMENT OF HUMAN DISEASES SUCH AS CANCER. THIS ARTICLE REVIEWS EXAMPLES OF VIRUSES AND BACTERIA KNOWN OR THOUGHT TO INDUCE EPIGENETIC CHANGES IN HOST CELLS, AND HOW THIS MIGHT CONTRIBUTE TO DISEASE. THE HERITABLE NATURE OF THESE PROCESSES IN GENE REGULATION SUGGESTS THAT THEY COULD PLAY IMPORTANT ROLES IN CHRONIC DISEASES ASSOCIATED WITH MICROBIAL PERSISTENCE; THEY MIGHT ALSO EXPLAIN SO-CALLED 'HIT-AND-RUN' PHENOMENA IN INFECTIOUS DISEASE PATHOGENESIS. 2010 16 3826 39 INVESTIGATION OF EPIGENETICS IN KIDNEY CELL BIOLOGY. EPIGENETICS IS THE STUDY OF HERITABLE CHANGES IN DNA OR ITS ASSOCIATED PROTEINS EXCEPT MUTATIONS IN GENE SEQUENCE. EPIGENETIC REGULATION PLAYS FUNDAMENTAL ROLES IN THE PROCESSES OF KIDNEY CELL BIOLOGY THROUGH THE ACTION OF DNA METHYLATION, CHROMATIN MODIFICATIONS VIA EPIGENETIC REGULATORS AND INTERACTION VIA TRANSCRIPTION FACTORS, AND NONCODING RNA SPECIES. KIDNEY DISEASES, INCLUDING ACUTE KIDNEY INJURY, CHRONIC KIDNEY DISEASE, NEPHRITIC AND NEPHROTIC SYNDROMES, PYELONEPHRITIS AND POLYCYSTIC KIDNEY DISEASES ARE DRIVEN BY ABERRANT ACTIVITY IN NUMEROUS SIGNALING PATHWAYS IN EVEN INDIVIDUAL KIDNEY CELL. EPIGENETIC ALTERATIONS, INCLUDING DNA METHYLATION, HISTONE ACETYLATION AND METHYLATION, NONCODING RNAS, AND PROTEIN POSTTRANSLATIONAL MODIFICATIONS, COULD DISRUPT ESSENTIAL PATHWAYS THAT PROTECT THE RENAL CELLS FROM UNCONTROLLED GROWTH, APOPTOSIS AND ESTABLISHMENT OF OTHER RENAL ASSOCIATED SYNDROMES, WHICH HAVE BEEN RECOGNIZED AS ONE OF THE CRITICAL MECHANISMS FOR REGULATING FUNCTIONAL CHANGES THAT DRIVE AND MAINTAIN THE KIDNEY DISEASE PHENOTYPE. IN THIS CHAPTER, WE BRIEFLY SUMMARIZE THE EPIGENETIC MECHANISMS IN KIDNEY CELL BIOLOGY AND EPIGENETIC BASIS OF KIDNEY DEVELOPMENT, AND INTRODUCE EPIGENETIC TECHNIQUES THAT CAN BE USED IN INVESTIGATING THE MOLECULAR MECHANISM OF KIDNEY CELL BIOLOGY AND KIDNEYS DISEASES, PRIMARILY FOCUSING ON THE INTEGRATION OF DNA METHYLATION AND CHROMATIN IMMUNOPRECIPITATION TECHNOLOGIES INTO KIDNEY DISEASE ASSOCIATED STUDIES. FUTURE STUDIES USING THESE EMERGING TECHNOLOGIES WILL ELUCIDATE HOW ALTERATIONS IN THE RENAL CELL EPIGENOME COOPERATE WITH GENETIC ABERRATIONS FOR KIDNEY DISEASE INITIATION AND PROGRESSION. INCORPORATING EPIGENOMIC TESTING INTO THE CLINICAL RESEARCH IS ESSENTIAL TO FUTURE STUDIES WITH EPIGENETICS BIOMARKERS AND PRECISION MEDICINE USING EMERGING EPIGENETIC THERAPIES. 2019 17 6340 36 THE ROLE OF EPIGENETIC FACTORS IN PSORIASIS. PSORIASIS IS A CHRONIC, SYSTEMIC, IMMUNE-MEDIATED DISEASE WITH AN INCIDENCE OF APPROXIMATELY 2%. THE PATHOGENESIS OF THE DISEASE IS COMPLEX AND NOT YET FULLY UNDERSTOOD. GENETIC FACTORS PLAY A SIGNIFICANT ROLE IN THE PATHOGENESIS OF THE DISEASE. IN PREDISPOSED INDIVIDUALS, MULTIPLE TRIGGER FACTORS MAY CONTRIBUTE TO DISEASE ONSET AND EXACERBATIONS OF SYMPTOMS. ENVIRONMENTAL FACTORS (STRESS, INFECTIONS, CERTAIN MEDICATIONS, NICOTINISM, ALCOHOL, OBESITY) PLAY A SIGNIFICANT ROLE IN THE PATHOGENESIS OF PSORIASIS. IN ADDITION, EPIGENETIC MECHANISMS ARE CONSIDERED RESULT IN MODULATION OF INDIVIDUAL GENE EXPRESSION AND AN INCREASED LIKELIHOOD OF THE DISEASE. STUDIES HIGHLIGHT THE SIGNIFICANT ROLE OF EPIGENETIC FACTORS IN THE ETIOLOGY AND PATHOGENESIS OF PSORIASIS. EPIGENETIC MECHANISMS IN PSORIASIS INCLUDE DNA METHYLATION, HISTONE MODIFICATIONS AND NON-CODING RNAS. EPIGENETIC MECHANISMS INDUCE GENE EXPRESSION CHANGES UNDER THE INFLUENCE OF CHEMICAL MODIFICATIONS OF DNA AND HISTONES, WHICH ALTER CHROMATIN STRUCTURE AND ACTIVATE TRANSCRIPTION FACTORS OF SELECTED GENES, THUS LEADING TO TRANSLATION OF NEW MRNA WITHOUT AFFECTING THE DNA SEQUENCE. EPIGENETIC FACTORS CAN REGULATE GENE EXPRESSION AT THE TRANSCRIPTIONAL (VIA HISTONE MODIFICATION, DNA METHYLATION) AND POSTTRANSCRIPTIONAL LEVELS (VIA MICRORNAS AND LONG NON-CODING RNAS). THIS STUDY AIMS TO PRESENT AND DISCUSS THE DIFFERENT EPIGENETIC MECHANISMS IN PSORIASIS BASED ON A REVIEW OF THE AVAILABLE LITERATURE. 2021 18 2524 36 EPIGENETICS AND THE UREMIC PHENOTYPE: A MATTER OF BALANCE. EPIGENETICS, WHICH IS THE STUDY OF CHANGES IN GENE EXPRESSION THAT OCCUR WITHOUT CHANGES IN DNA SEQUENCE, IS A NOVEL DISCIPLINE THAT HAS LANGUISHED IN THE SHADOW OF ITS GENOMIC BIG BROTHER. SO FAR, STUDIES OF THE EPIGENOME HAVE ATTRACTED LITTLE INTEREST IN NEPHROLOGY. CHRONIC KIDNEY DISEASE IS AN EXAMPLE OF COMPLEX DISEASE IN WHICH THE PHENOTYPE ARISES FROM A COMBINATION OF ENVIRONMENTAL AND HERITABLE FACTORS. EVIDENCE SUGGESTS THAT THE CONTRIBUTION MADE BY THE ENVIRONMENT MAY BE MEDIATED VIA MODIFICATIONS OF THE EPIGENOME. IN THE UREMIC MILIEU, SEVERAL FEATURES SUCH AS INFLAMMATION, DYSLIPIDEMIA, HYPERHOMOCYSTEINEMA, OXIDATIVE STRESS AS WELL AS VITAMIN AND NUTRITIONAL DEFICIENCIES MAY AFFECT ABERRANT GLOBAL DNA METHYLATION. HOWEVER, AS HYPERHOMOCYSTEINEMIA SEEMS TO PROMOTE GLOBAL DNA HYPOMETHYLATION AND PERSISTENT INFLAMMATION DNA HYPERMETHYLATION, THE EFFECTS OF THE UREMIC MILIEU ON ABERRANT GLOBAL DNA METHYLATION MAY BE COMPLEX AND CONTEXT-SENSITIVE. IT SHOULD BE EMPHASIZED THAT IN ANALOGY TO THE UNSPECIFIC NATURE OF FEVER, ABERRANT GLOBAL DNA METHYLATION IS ONLY A SIGN OF A GENERALIZED EPIGENETIC DYSREGULATION. THUS, TO PROVIDE BETTER UNDERSTANDING OF THE EFFECTS OF ABERRANT DNA METHYLATION ON THE UREMIC PHENOTYPE, FURTHER STUDIES EVALUATING SITE-SPECIFIC INFORMATION ON METHYLATION IN VARIOUS CANDIDATE GENES ARE NEEDED. THE SCIENCE OF EPIGENETICS MAY NOT ONLY UNCOVER ETIOLOGIC AND PATHOGENIC MECHANISMS IN UREMIA, BUT MAY ALSO BE OF HELP TO DEVELOP NOVEL TREATMENT STRATEGIES TARGETING THE UNACCEPTABLE HIGH DEATH RISK IN CARDIOVASCULAR COMPLICATIONS IN THIS PATIENT POPULATION. 2008 19 6378 41 THE ROLE OF NUTRITION ON EPIGENETIC MODIFICATIONS AND THEIR IMPLICATIONS ON HEALTH. NUTRITION PLAYS A KEY ROLE IN MANY ASPECTS OF HEALTH AND DIETARY IMBALANCES ARE MAJOR DETERMINANTS OF CHRONIC DISEASES INCLUDING CARDIOVASCULAR DISEASE, OBESITY, DIABETES AND CANCER. ADEQUATE NUTRITION IS PARTICULARLY ESSENTIAL DURING CRITICAL PERIODS IN EARLY LIFE (BOTH PRE- AND POSTNATAL). IN THIS REGARD, THERE IS EXTENSIVE EPIDEMIOLOGIC AND EXPERIMENTAL DATA SHOWING THAT EARLY SUB-OPTIMAL NUTRITION CAN HAVE HEALTH CONSEQUENCES SEVERAL DECADES LATER. THE HYPOTHESIS THAT EPIGENETIC MECHANISMS MAY LINK SUCH NUTRITIONAL IMBALANCES WITH ALTERED DISEASE RISK HAS BEEN GAINING ACCEPTANCE OVER RECENT YEARS. EPIGENETICS CAN BE DEFINED AS THE STUDY OF HERITABLE CHANGES IN GENE EXPRESSION THAT DO NOT INVOLVE ALTERATIONS IN THE DNA SEQUENCE. EPIGENETIC MARKS INCLUDE DNA METHYLATION, HISTONE MODIFICATIONS AND A VARIETY OF NON-CODING RNAS. STRIKINGLY, THEY ARE PLASTIC AND RESPOND TO ENVIRONMENTAL SIGNALS, INCLUDING DIET. HERE WE WILL REVIEW HOW DIETARY FACTORS MODULATE THE ESTABLISHMENT AND MAINTENANCE OF EPIGENETIC MARKS, THEREBY INFLUENCING GENE EXPRESSION AND, HENCE, DISEASE RISK AND HEALTH. 2012 20 2330 42 EPIGENETIC REGULATION OF IMMUNE FUNCTION IN ASTHMA. ASTHMA IS A COMMON COMPLEX RESPIRATORY DISEASE CHARACTERIZED BY CHRONIC AIRWAY INFLAMMATION AND PARTIALLY REVERSIBLE AIRFLOW OBSTRUCTION RESULTING FROM GENETIC AND ENVIRONMENTAL DETERMINANTS. BECAUSE EPIGENETIC MARKS INFLUENCE GENE EXPRESSION AND CAN BE MODIFIED BY BOTH ENVIRONMENTAL EXPOSURES AND GENETIC VARIATION, THEY ARE INCREASINGLY RECOGNIZED AS RELEVANT TO THE PATHOGENESIS OF ASTHMA AND MAY BE A KEY LINK BETWEEN ENVIRONMENTAL EXPOSURES AND ASTHMA SUSCEPTIBILITY. UNLIKE CHANGES TO DNA SEQUENCE, EPIGENETIC SIGNATURES ARE DYNAMIC AND REVERSIBLE, CREATING AN OPPORTUNITY FOR NOT ONLY THERAPEUTIC TARGETS BUT MAY SERVE AS BIOMARKERS TO FOLLOW DISEASE COURSE AND IDENTIFY MOLECULAR SUBTYPES IN HETEROGENEOUS DISEASES SUCH AS ASTHMA. IN THIS REVIEW, WE WILL EXAMINE THE RELATIONSHIP BETWEEN ASTHMA AND 3 KEY EPIGENETIC PROCESSES THAT MODIFY GENE EXPRESSION: DNA METHYLATION, MODIFICATION OF HISTONE TAILS, AND NONCODING RNAS. IN ADDITION TO PRESENTING A COMPREHENSIVE ASSESSMENT OF THE EXISTING EPIGENETIC STUDIES FOCUSING ON IMMUNE REGULATION IN ASTHMA, WE WILL DISCUSS FUTURE DIRECTIONS FOR EPIGENETIC INVESTIGATION IN ALLERGIC AIRWAY DISEASE. 2022